Cosmo is a fully-integrated specialty pharmaceutical company that develops novel formulation of off-patent drugs. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases, such as Ulcerative Colitis and Crohn’s Disease, as well as for colon infections. Cosmo was formed by buyout of Parke Davis' (now Pfizer Group) manufacturing facility in Lainate (Milan), Italy.

Acquired Companies: Cosmo Research_and_ Development SpA